## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup> EDWARDS MARK G					ACI	2. Issuer Name and Ticker or Trading Symbol ACELRX PHARMACEUTICALS INC [ ACRX]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (specify				ner
(Last) (First) (Middle) C/O ACELRX PHARMACEUTICALS, INC.						3. Date of Earliest Transaction (Month/Day/Year) 06/15/2017								below) below)			Jeeny	
351 GALVESTON DRIVE					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person				
(Street) REDWC CITY	OOD C.	A 9	94063										2		•		orting Perso One Repo	
(City)	(S	tate) (	Zip)															
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day						Execution Date,			Transaction Disposed Code (Instr. and 5)			ies Acquired (A) or Of (D) (Instr. 3, 4		5. Amou Securitie Beneficia Owned Followin	s Form Illy (D) o Indi		n:Director Frect (I)	7. Nature of Indirect Beneficial Ownership Instr. 4)
							Code	v	Amount	(A) or (D) Price		Reported Transaction(s) (Instr. 3 and 4)		(iiiou	,	1501. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned         (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, rity or Exercise (Month/Day/Year) if any			4. Transactior Code (Instr 8)		on of		6. Date Exercisable at Expiration Date (Month/Day/Year)		1	Amount of Securities Underlying Derivative Security (Instr and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisat	le	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy) <sup>(1)</sup>	<b>\$</b> 2.3	06/15/2017			A		15,000		07/15/201	7 <sup>(2)(3)</sup>	06/14/2027	Common Stock	15,000	\$0	15,00	0	D	

Explanation of Responses:

1. Issued pursuant to the 2011 Equity Incentive Plan.

2. The shares subject to the option vest as follows: 1/24th of the shares subject to the option vest in equal monthly installments over 24 months, subject to Optionee's Continuous Service on the Company's Board of Directors.

3. 100% Acceleration upon Change of Control.

<u>/s/ Martha Ad</u>	ler, Attorney	<u>In</u> 06/15/2017
Fact		00/15/2017

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.